JPRN-jRCTs031210326进行中（未招募）未知
A multicenter study to evaluate the effectiveness of budesonide enema foam treatment and the usefulness ofserum biomarker measurement for active ulcerative colitis - BF-LRG
Matsuoka Katsuyoshi0 个研究点目标入组 20 人开始时间: 2021年9月21日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 16age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Include patients with mild to moderate UC who meet all the following 1 to 6.
- •1. Patients diagnosed with UC according to the ulcerative colitis/Crohn's disease diagnostic criteria and treatment guidelines (revised in 2019)
- •2. Patients whose total Mayo score evaluated on the eligibility confirmation date was 10 points or less and each sub-score met the following.
- •(1) Patients with MES >_ 2 at the most active site from the rectum to the sigmoid colon and <_ 1 at the proximal site beyond the sigmoid colon on colonoscopy performed on the eligibility confirmation date.
- •(2) Patients with a physician's general assessment score of 1-2 on the eligibility confirmation date.
- •3. Gender: Not specified.
- •4. Age: 16 years or older (at the time of acquisition of Consent)
- •5. Visit classification: Outpatient
- •6. Patients who can obtain written consent (however, if the patient is under 20 years old, obtain written consent from the substitute)
排除标准
- •1.Patients who received the following pharmacotherapy or treatment within the period of time as shown below:
- •[Two weeks before the start date of study drug administration]
- •New addition of mesalazine preparation (enema / suppository) and salazosulfapyridine preparation (suppository)
- •Antidiarrheal drug
- •Bowel cleaning composition (Except used for pre-preparation of colonoscopy in this clinical study)
- •Laxatives (Except used for pre-preparation of colonoscopy in this clinical study)
- •Enema (Except used for pre-preparation of colonoscopy in this clinical study)
- •[Four weeks before the start date of study drug administration]
- •If the dose of Mesalazine formulations is over then 4.0 g/day (excluding Asacol tablets and Rialda tablets)
- •If the dose of Asacol tablets is over then 3.6 g/day
- •If the dose of Rialda tablets is over then 4.8 g/day.
- •If the dose of Salazosulfapyridine formulation is over then 8.0 g/day
- •Leukocytapheresis
- •Antibiotics or antibacterial drugs for the treatment of UC.
- •Live vaccines
- •[Eight weeks before the start date of study drug administration]
- •Corticosteroid formulations (oral, enema, suppositories, hemorrhoid treatment, inhalants, injections)
- •[Twelve weeks before the start date of study drug administration]
- •Immunomodulators(cyclosporine, tacrolimus, methotrexate, azathioprine,6-mercaptopurine)
- •Antibody preparation (anti-TNFa antibody agents, vedolizumab, ustekinumab)
- •JFK inhibitors (tofacitinib)
- •2. Patients who have changed the dosage or administration of the following drug therapies within the following period:
- •[One weeks before the start date of study drug administration]
- •[Two weeks before the start date of study drug administration]
- •Mesalazine preparation (enema / suppository), salazosulfapyridine preparation (suppository)
- •[Four weeks before the start date of study drug administration]
- •Mesalazine formulations (oral), salazosulfapyridine formulation preparation (oral)
- •3. Patients with a history of resection of the sigmoid colon or rectum (excluding polypectomy), or patients scheduled for surgical treatment of the gastrointestinal tract during the study period.
- •4. Patients who are suspected clinically to have infectious enteritis.
- •5. Patients with infectious diseases and deep mycoses for which there is no effective antibacterial agent.
- •6. Patients with serious heart disease, nephropathy, or hepatic disorder
- •7. Patients with (or suspected to diagnosed with) malignant tumor
- •8. Female patients who are pregnant, lactating, or who may be pregnant
- •9. Patients who wish to become pregnant during the administration period of this study drug, or female patients who do not agree with using any appropriate medical methods for contraception (concomitant use of intrauterine devices, pessaries, or partner condoms, etc. However, the use of oral contraceptives is excluded).
- •10. Patients with a history of allergic reaction to budesonide
- •11. Patients who are receiving desmopressin acetate hydrate
- •12. Patients who participated in other clinical trials within 12 weeks prior to any examination or observation specified in this study protocol
- •13. Other patients who are judged to be inappropriate for this study by the principal investigator, etc.
研究者
相似试验
已完成
2 期
Multi-center study to evaluate the efficacy and to standardize RFA for early breast cancerEarly breast cancerJPRN-UMIN000008675ational Cancer Center Hospital372
尚未招募
不适用
A multicenter clinical study to test the efficacy and safety of C1-inhibitor concentrate for clinical amniotic fluid embolism.clinical amnitotic fluid embolismJPRN-UMIN000012273Department of Obstetrics and Gynecology, Mie university hospital.5
已完成
不适用
Investigating the effect and safety of the Satisphere™ insert in overweight patientsObesityISRCTN81340421Endosphere Inc (USA)60
招募中
Unknown
A multicenter interventional study on the efficacy and safety of continuous absorbable barbed sutures in rectus abdominis muscle fascia closure technique during free abdominal flap harvesting.JPRN-jRCT1052230095omura Tadashi90
已完成
不适用
A multicentre study to determine the efficacy and patient acceptability of scalp cooling in the prevention of docetaxel-induced hair lossCancerISRCTN00283877eiden University Medical Centre (LUMC) (The Netherlands)260